INOVIO Pharmaceuticals, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter report. INOVIO is a clinical-stage biotechnology company developing DNA medicines and CELLECTRA delivery devices; it had no approved products or product-sale revenue. The financial statements received an unqualified independent auditor opinion.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $0.8 million | $10.3 million |
| Research and development expense | $86.7 million | $187.7 million |
| General and administrative expense | $47.6 million | $90.2 million |
| Total operating expenses | $144.8 million | $277.8 million |
| Operating loss | $143.9 million | $267.6 million |
| Net loss | $135.1 million | $279.8 million |
| Net loss per share | $6.09 | $14.07 |
| Cash used in operations | $124.4 million | $216.2 million |
Revenue fell 92%, principally because the Department of Defense procurement contract was completed in 2022. ApolloBio accounted for 29% of 2023 revenue, or approximately $245,000. No product revenue was reported; product margins are therefore not meaningful.
At December 31, 2023, cash and short-term investments totaled $145.3 million, versus $253.0 million a year earlier; working capital was $110.5 million, versus $218.4 million. Accumulated deficit was $1.6 billion. Management expected the existing resources to fund planned operations for at least 12 months from the report date and estimated cash runway into the second quarter of 2025, excluding further financing. The company stated that additional capital would be needed to complete development and commercialize candidates.
Year-end convertible senior notes had a carrying value of $16.8 million and carried a 6.50% coupon. They matured and were repaid in full for approximately $16.9 million, including accrued interest, on March 1, 2024, from existing cash. Operating lease liabilities totaled $13.4 million. The company raised $5.5 million net through its at-the-market equity program in 2023 and reported an additional $5.2 million of net proceeds from share sales between January 1 and the report date.
Material changes and unusual items
- Net loss improved by 52% and operating expenses fell 48%, largely reflecting reduced COVID-19 program spending and restructuring-related cost reductions. R&D expense decreased 54%; INO-3107 R&D spending rose to $17.8 million from $8.1 million.
- Revenue declined sharply after the DoD procurement contract generated no revenue in 2023, compared with $9.6 million in 2022.
- INOVIO recorded a $10.5 million non-cash goodwill impairment and a $2.0 million intangible-asset impairment. It also reported a $5.9 million unrealized gain on available-for-sale equity securities and $4.8 million of realized losses on short-term investment sales.
- The securities class-action settlement included $14.0 million in common shares; insurers funded its $30.0 million cash component. The company also paid $1.2 million in plaintiffs’ legal fees under a derivative-litigation settlement and implemented governance reforms.
- A 1-for-12 reverse stock split became effective January 24, 2024; share and per-share amounts in the filing are adjusted retrospectively.
Pipeline, outlook and principal risks
- INO-3107 for recurrent respiratory papillomatosis (RRP): In the completed Phase 1/2 trial, 81.3% of 32 patients had fewer surgical interventions in the year after treatment than in the prior year; 28.1% required no surgery during or after the dosing window. INOVIO reported mostly low-grade adverse events. The FDA said the trial data could support a BLA submission under accelerated approval. The company still must meet filing requirements and initiate a confirmatory trial before submission; FDA acceptance or approval is not assured. INO-3107 has FDA Breakthrough Therapy and Orphan Drug designations.
- Portfolio reprioritization: INOVIO discontinued U.S. development of VGX-3100 for cervical HSIL after REVEAL2 failed to reach statistical significance in its biomarker-selected primary population, although the all-participants secondary analysis was statistically significant. ApolloBio continues a Phase 3 trial in China. INOVIO also discontinued VGX-3100 development for vulvar HSIL and ended internally funded INO-4800 COVID-19 development in 2022.
- Other programs: INO-3112 is being considered for a Phase 3 OPSCC study with Coherus supplying toripalimab, subject to FDA alignment on study design. INO-5401 GBM follow-up and other early-stage programs remain dependent on development progress and collaboration resources.
- Operating outlook: Management cited headcount reductions and a narrower development plan as drivers of lower spending and extended runway. The company had approximately 122 full-time employees as of February 2024, down from more than 300 in early 2022. There is no company-issued revenue or profitability guidance in the provided filing text.
- Key risks: Continuing losses, limited and variable collaboration or grant revenue, need for additional financing and potential shareholder dilution; clinical, regulatory and manufacturing uncertainty; reliance on third parties and some single-source suppliers; competition, especially in RRP; and unresolved VGXI and GeneOne litigation. Other disclosed exposures include China-related collaboration and supply risks, intellectual-property disputes, and cybersecurity and data-privacy risks.
Most important facts for investors to verify
- Whether INOVIO initiates the required INO-3107 confirmatory trial and satisfies FDA requirements for an accelerated-approval BLA; the FDA’s feedback is not an approval decision.
- Whether the stated cash runway into Q2 2025 remains achievable after note repayment, ongoing operating cash use, and any further financing or share issuance.
- Whether INO-3107’s trial results are confirmed in the next study and translate into regulatory approval, reimbursement, and commercial adoption.
- Progress and funding responsibility for the China VGX-3100 program, the planned INO-3112 study, and other retained pipeline programs.
- Developments in VGXI and GeneOne litigation, manufacturing capacity, and the effects of the workforce reductions on execution.